Live Breaking News & Updates on Recursion Pharmaceuticals Company Profile|Page 7

Stay updated with breaking news from Recursion pharmaceuticals company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Platinum Investment Management Ltd. Has $18.48 Million Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Platinum Investment Management Ltd. grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 2.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,770,451 shares of the company’s stock after buying an additional 60,112 shares during the period. Platinum Investment Management Ltd.’s […] ....

Tina Marriott Larson , Blake Borgeson , Recursion Pharmaceuticals Trading , Baillie Gifford Co , News Ratings For Recursion Pharmaceuticals Daily , Platinum Investment Management Ltd , Needham Company , Recursion Pharmaceuticals , Securities Exchange Commission , Artal Group , Schroder Investment Management Group , Sg Americas Securities , Alpine Global Management , Recursion Pharmaceuticals Inc , Recursion Pharmaceuticals Company Profile , Quarter For Recursion Pharmaceuticals , Morgan Stanley , Platinum Investment Management , Free Report , Investment Management , Global Management , Investment Management Group , Director Blake Borgeson , Marriott Larson , Get Free Report , Visit Holdingschannel ,

Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading Volume

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares saw unusually-strong trading volume on Thursday . Approximately 1,231,280 shares traded hands during trading, a decline of 61% from the previous session’s volume of 3,169,160 shares.The stock last traded at $8.81 and had previously closed at $9.38. Analysts Set New Price Targets A number of analysts […] ....

Blake Borgeson , Christopher Gibson , Recursion Pharmaceuticals Company Profile , Needham Company , Recursion Pharmaceuticals Stock Down , Morgan Stanley , Daiwa Securities Group Inc , Allspring Global Investments Holdings , News Ratings For Recursion Pharmaceuticals Daily , Insider Activity At Recursion Pharmaceuticals , Recursion Pharmaceuticals , Recursion Pharmaceuticals Inc , Get Free Report , Pharmaceuticals Stock Down , Director Blake Borgeson , Wealth Management , Securities Group , Global Investments Holdings , Recursion Pharmaceuticals Daily , Nasdaq Rxrx ,

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora Sells 25,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora Sells 25,000 Shares of Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Michael Secora , Hedge Funds Weigh In On Recursion Pharmaceuticals , York Mellon Corp , Recursion Pharmaceuticals Company Profile , Recursion Pharmaceuticals Inc , Morgan Stanley , Recursion Pharmaceuticals Stock , Securities Exchange Commission , News Ratings For Recursion Pharmaceuticals Daily , Vanguard Group Inc , Recursion Pharmaceuticals , Needham Company , Quarter For Recursion Pharmaceuticals , Swiss National Bank , Metlife Investment Management , Get Free Report , Exchange Commission , National Bank , New York Mellon Corp , Life Investment Management , Vanguard Group , Recursion Pharmaceuticals Daily ,

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 17,770 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 17,770 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $11.16, for a total transaction of $198,313.20. Following the completion of the sale, the director now directly owns 7,469,615 shares of […] ....

Blake Borgeson , Foundations Investment Advisors , Morgan Stanley , Manufacturers Life Insurance Company , Securities Exchange Commission , Institutional Investors Weigh In On Recursion Pharmaceuticals , Recursion Pharmaceuticals Price Performance , Needham Company , Quarter For Recursion Pharmaceuticals , Principal Financial Group Inc , Recursion Pharmaceuticals Company Profile , News Ratings For Recursion Pharmaceuticals Daily , Vident Investment Advisory , Recursion Pharmaceuticals , Recursion Pharmaceuticals Inc , Get Free Report , Director Blake Borgeson , Exchange Commission , Financial Group , Investment Advisors , Investment Advisory , Recursion Pharmaceuticals Daily ,

Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells 17,770 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 17,770 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $11.16, for a total value of $198,313.20. Following the sale, the director now directly owns 7,469,615 shares in the company, valued […] ....

Blake Borgeson , Baillie Gifford Co , Morgan Stanley , Recursion Pharmaceuticals Trading Down , Alpine Global Management , Cypress Point Wealth Management , Hedge Funds Weigh In On Recursion Pharmaceuticals , Needham Company , Quarter For Recursion Pharmaceuticals , Recursion Pharmaceuticals Inc , Recursion Pharmaceuticals Company Profile , News Ratings For Recursion Pharmaceuticals Daily , Schroder Investment Management Group , Recursion Pharmaceuticals , Get Free Report , Director Blake Borgeson , Pharmaceuticals Trading Down , Global Management , Point Wealth Management , Investment Management Group , Baillie Gifford , Recursion Pharmaceuticals Daily ,